



NexImmune Announces Management and Board Appointments

March 27, 2018

- **Scott Carmer appointed Chief Executive Officer**
- **Kristi Jones promoted to Chief Operating Officer**
- **Alan Roemer appointed Chairman of the Board of Directors**

GAITHERSBURG, Md., March 27, 2018 (GLOBE NEWSWIRE) -- NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that Scott Carmer has been appointed Chief Executive Officer. Mr. Carmer has served as NexImmune's Chief Operating Officer since 2015. In addition, Kristi Jones has been promoted to Chief Operating Officer, and Alan Roemer has been appointed as Chairman of the Board of Directors.

"I am pleased to congratulate Scott and Kristi, both respected and valued leaders within the organization, on their well-deserved promotions," said Alan Roemer, Chairman of NexImmune. "They have each played an integral role advancing the company's immuno-oncology programs towards the clinic and closing our \$24 million Series A Financing. I look forward to working with the leadership team and Board of Directors to bring NexImmune's antigen-specific AIM adoptive cellular therapy to patients in need."

Scott P. Carmer

Scott Carmer joined NexImmune in February 2014 as the Company's first Chief Business Officer and was promoted to Chief Operating Officer in July 2015. Prior to joining NexImmune, Mr. Carmer served as Executive Vice President, Commercial Operations at MedImmune from 2010 through 2013, where he was responsible for all sales, marketing, Medical Affairs, Managed Markets, Global Marketing & Alliances, and commercial analytics functions. He was previously Genentech's Vice President, Immunology from 2006-2010, responsible for the US launches of Rituxan and ACTEMRA. Prior to Genentech, Mr. Carmer held several leadership roles of increasing responsibility at Amgen, most recently as Executive Director of global marketing, Immunology and Oncology and at GlaxoSmithKline, where he held key roles in global brand management, business development, commercial operations, managed care and field sales. Scott received his B.S. in Biology from the University of Kentucky.

Kristi Jones

Kristi Jones joined NexImmune in 2017 where she served as the Chief Business Officer. She served as NexImmune's interim CBO in 2016. Prior to joining NexImmune, Ms. Jones was Vice President of Portfolio Strategy and Management at Astra Zeneca, where she played an instrumental role in building a scientifically innovative, diverse portfolio creating new value for the company. Prior to that she served at MedImmune, as Vice President of Global Strategic Marketing and payor planning where she focused driving value through differentiating products, establishing to market strategies and preparing MedImmune for multiple product launches. Previously, Ms. Jones held multiple leadership roles with increasing responsibility at Genentech, where she worked for 16 years, including Head of Immunology and Ophthalmology Pipeline Development - Global Portfolio and Product Strategy, Commercial Operations and Endocrine and Respiratory Franchise leadership. Kristi has held global and US roles in commercial, operations, strategy and business development. She received her B.S. in Biology from Texas Tech University Health Sciences Center and a pharmacy degree from The University of Texas at Austin.

Alan S. Roemer

Alan Roemer has served on NexImmune's Board of Directors since 2017. Mr. Roemer is also a founding leadership team member of Roivant Sciences and has served as Senior Vice President, Corporate Development since July 2016. He previously served as Roivant's Senior Vice President, Finance & Operations from the company's inception through June 2016 and Chief Financial Officer of Axovant Sciences in 2015. From 2009 to 2014, Mr. Roemer was a Managing Director for the Trout Group, where he provided financing, strategic advisory and investor relations services for life sciences clients. He previously served as Chief Financial Officer & Treasurer of Zelos Therapeutics and was a Vice President at Pharmasset (acquired by Gilead) from 1999 to 2008. Prior to Pharmasset, Mr. Roemer was a healthcare consultant for Booz-Allen & Hamilton and Deloitte Consulting, and he held various operational roles at Bank of America. Mr. Roemer currently serves as a trustee of the Helene Fuld College of Nursing. He received his B.S. in Business Administration from Georgetown University and his M.B.A. and M.P.H. degrees from Emory University's Goizueta Business School and Rollins School of Public Health.

About NexImmune

NexImmune is a biopharmaceutical company with a mission to help cure cancer by directing T cell function using precision technology and personalized therapeutics. The Company's proprietary AIM Technology uses artificial Antigen Presenting Cells (aAPC) to create highly targeted T cell-based immunotherapies. In preclinical studies, aAPC have demonstrated the ability to clear established tumors by expanding antigen-specific T cells when injected directly (in vivo) or when used as part of an ex vivo cellular expansion system. For more information visit: www.neximmune.com

The Leukemia & Lymphoma Society is a NexImmune partner for the clinical development of AIM ACT.

Contact

Chad Rubin
Solebury Trout
+1 (646) 378-2947
crubin@troutgroup.com